Lantheus Holdings (LNTH) Long-Term Deferred Tax (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Long-Term Deferred Tax of $89.1 million for Q1 2026, down 47.23% year-over-year from $168.9 million in Q1 2025, and down 18.38% quarter-over-quarter from $109.2 million in Q4 2025.
Lantheus Holdings (LNTH) Long-Term Deferred Tax (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Long-Term Deferred Tax for 13 consecutive years, with $89.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Deferred Tax fell 47.23% year-over-year to $89.1 million; the TTM figure through Mar 2026 stood at $89.1 million (down 47.23% YoY), while the FY2025 annual figure was $109.2 million, down 35.85% from the prior year.
- Long-Term Deferred Tax slipped to $89.1 million in Q1 2026 per LNTH's latest filing, from $109.2 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $170.2 million in Q4 2024 and bottomed at $46.8 million in Q3 2022.
- Historically, Long-Term Deferred Tax has averaged $120.5 million across 5 years, with a median of $134.2 million in 2023.
- Annual changes were most pronounced in 2023 — Long-Term Deferred Tax surged 225.15% — and 2026, when it slumped 47.23%.
- Lantheus Holdings' Long-Term Deferred Tax stood at $110.6 million in 2022, then soared by 35.75% to $150.2 million in 2023, then gained by 13.34% to $170.2 million in 2024, then tumbled by 35.85% to $109.2 million in 2025, then decreased by 18.38% to $89.1 million in 2026.
- Business Quant data shows LNTH's Long-Term Deferred Tax at $89.1 million in Q1 2026, $109.2 million in Q4 2025, and $107.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Lantheus Holdings | 6.54 Bn | 5.94 Bn | 241.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 102.72 Mn |
| Mar 31, 2026 | 89.12 Mn |
| Dec 31, 2025 | 109.20 Mn |
| Sep 30, 2025 | 107.45 Mn |
| Jun 30, 2025 | 138.26 Mn |
| Mar 31, 2025 | 168.89 Mn |
| Dec 31, 2024 | 170.23 Mn |
| Sep 30, 2024 | 144.64 Mn |
| Jun 30, 2024 | 151.19 Mn |
| Mar 31, 2024 | 138.90 Mn |
| Dec 31, 2023 | 150.20 Mn |
| Sep 30, 2023 | 152.19 Mn |
| Jun 30, 2023 | 134.20 Mn |
| Mar 31, 2023 | 133.87 Mn |
| Dec 31, 2022 | 110.65 Mn |
| Sep 30, 2022 | 46.81 Mn |
| Jun 30, 2022 | 55.16 Mn |
| Mar 31, 2022 | 47.87 Mn |
| Dec 31, 2021 | 62.76 Mn |
| Sep 30, 2021 | 66.49 Mn |